Abstract
Long-term carcinogenicity of Ftorafur (Tegafur) was studied in rodents. Rats and mice were treated for one year per os with 40 (mice) and 60 (rat) mg/kg Ftorafur twice a week and were followed for their entire life. Analysis of the data provide no evidence for the carcinogenicity of Ftorafur in rodents. These findings are similar to other antimetabolite studies and contrasts with the carcinogenic alkylating agents.
This is a preview of subscription content, log in via an institution to check access.
References
IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Suppl. 7. Lyon, France, 1987, pp. 40–42.
IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Vol 50. Lyon, France, 1990, pp. 47–145.
Germane S, Gilev A, Zidemiane A, Zhiik R, Meirena D: Ftorafur, „Zinatne“, Riga, 1979.
Uchino T, Hata I, Sasaki M, Samejimu N, Tanabe T, Hayasaka H, Asaishi K, Mito M: Post-operative adjuvant chemoendocrine therapy with Ftorafur and Tamoxifen in breast cancer: J Cane Res Clin Oncol S1, 116:200, 1990.
Abe R, Tsuchia A, Kikuchi K, Koie H, Cho K, Sailo K, Abo S, Tsukamoto M, Matsumoto M, Mori S, Yoshida F: Cooperative adjuvant therapy with Ftorafur and Tamoxifen in breast cancer. J Cane Res Clin Oncol S1, 116:201, 1990.
Wada T, Houjou T, Yasutomi M: Combination therapy with Medroxyprogesterone acetate, and Tegafur for Tamoxifen- and Adriamycin-resistant advanced breast cancer. J Cane Res Clin Oncol S1, 116:401, 1990.
Arima S, Ohsato K, Ohkuma R, Fukuyama N, Yanaouchi A, Hisatsugu T, Yamamoto X, Nakamura T, Abe R, Taira A, Shimura H: Multihospital randomized study on adjuvant chemotherapy with Mitomycin and Ftorafur or UFT for gastric cancer. J Cane Res Clin Oncol S1, 116:672, 1990.
Kochi M, Fujii M, Sawa H, Yamagata M, Susuki K, Watanabe Y, Mochizuki F, Yeda T, Iwai S, Tanaka T, Sakabe T: Induction (neoadjuvant) chemotherapy for colorectal cancer by orally administered Fluoropyrimidine. J Cane Res Clin Oncol S1, 116:684, 1990.
Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama Kumada H: A prospective randomized evaluation of a compound Tegafur and Uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Am J Clin Oncol 18: 204–210, 1995.
Ichinose Y, Takanashi N, Yano T, Asoh H, Yokoyama H, Tayama K, Hara N, Ohta M: A phase II trial of oral tegafur and Uracil plus cis-platin in patients with inoperable nonsmall cell lung cancer. Cancer 75: 2677–2680, 1995.
lnyyama Y: Long-term follow up of the patients with recurrent or advanced head and neck cancer who received chemotherapy for palliation. Proceedings of the IVth Int. Congress on Anticancer Chemotherapy, Paris, 1993, p. 68.
Tomatis L, Aitio A, Day NE, Heseltine E, et al: Drugs and exogenous sex hormones. Cancer: Causes Occurrences and Control. IARC Sci Publ No 100, Lyon, 1990, pp. 148–154
IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Vol. 26, Lyon. 1981, pp. 217–235.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Griciuté, L., Domkiené, V. Experimental study on the carcinogenicity of the Cytostatic drug ftorafur (tegafur). Pathol. Oncol. Res. 2, 69–70 (1996). https://doi.org/10.1007/BF02893954
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893954